文献速递慢性肾脏病水电解质与酸碱

尿酸转运蛋白ABCG2功能与无症状高尿酸血症:慢性肾脏病进展的回顾性队列研究

Urate Transporter ABCG2 Function and Asymptomatic Hyperuricemia: A Retrospective Cohort Study of CKD Progression.
PubMed 文献 · Am J Kidney Dis · 2022-07-08

该回顾性队列研究纳入2007至2017年间1,885名接受常规健康随访的日本成人,其中311例有无症状高尿酸血症,按估计ABCG2功能分为完整、75%和≤50%三组。结果显示无症状高尿酸血症总体与eGFR下降无关,但在eGFR 60-89 mL/min/1.73 m2且ABCG2功能≤50%者中相关;SUA≥6.0 mg/dL且eGFR 60-89 mL/min/1.73 m2者中,ABCG2功能≤50%较完整功能者eGFR下降约快1.2倍。

要点

  • 无症状高尿酸血症总体与eGFR下降无关。
  • eGFR 60-89 mL/min/1.73 m2且ABCG2功能≤50%者中,无症状高尿酸血症与eGFR下降相关(P=0.03)。
  • SUA≥6.0 mg/dL且eGFR 60-89 mL/min/1.73 m2者中,ABCG2功能≤50%较完整功能者eGFR下降约快1.2倍(P=0.02)。

核心结论

  • 无症状高尿酸血症与eGFR下降无关,除非存在ABCG2功能≤50%。

研究设计与样本

  • 回顾性队列研究,纳入2007至2017年间接受常规健康随访的1,885名日本成人,其中311例有无症状高尿酸血症(SUA>7.0 mg/dL),基线eGFR≥60 mL/min/1.73 m2,按估计ABCG2功能分为完整、75%和≤50%三组。

主要发现

  • 无症状高尿酸血症总体与eGFR下降关联微弱。
  • eGFR 60-89 mL/min/1.73 m2且ABCG2功能≤50%者中,无症状高尿酸血症与eGFR下降相关(P=0.03)。
  • SUA<6.0 mg/dL时,ABCG2与eGFR下降无关。
  • SUA≥6.0 mg/dL且eGFR 60-89 mL/min/1.73 m2者中,ABCG2功能≤50%较完整功能者eGFR下降约快1.2倍(P=0.02)。
  • SUA≥6.0 mg/dL且eGFR 60-89 mL/min/1.73 m2者中,校正后eGFR斜率(均值±均值标准误,mL/min/1.73 m2/年)分别为完整功能-0.946±0.049、75%功能-1.040±0.046、≤50%功能-1.148±0.069。

局限性

  • 缺乏对ABCG2已知转运的尿酸盐和尿毒症毒素的测量。
  • 无独立验证队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Treatment of asymptomatic hyperuricemia is not commonly implemented. However, it is unclear whether urate deposition that begins during asymptomatic hyperuricemia can induce nephropathy. Dysfunction of ATP-binding cassette subfamily G member 2 (ABCG2), a urate efflux transporter, leads to elevated serum uric acid concentration (SUA). We investigated the association between asymptomatic hyperuricemia and decreased estimated glomerular filtration rate (eGFR), and the impact of ABCG2 on this relationship. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 1,885 Japanese adults undergoing routine health care follow-up between 2007 and 2017 who had eGFR ≥60 mL/min/1.73 m2, of which 311 had asymptomatic hyperuricemia (SUA >7.0 mg/dL). Study participants were classified into 3 categories of estimated ABCG2 function (full, 75%, and ≤50% function). PREDICTORS: Baseline SUA and estimated ABCG2 function. OUTCOME: Change in eGFR over time. ANALYTICAL APPROACH: Linear mixed-effect models were used to analyze the relationship between asymptomatic hyperuricemia, ABCG2 function, and eGFR decline. RESULTS: Asymptomatic hyperuricemia was negligibly associated with eGFR decline overall. However, among those with eGFR 60-89 mL/min/1.73 m2 and ≤50% ABCG2 function, eGFR decline was associated with asymptomatic hyperuricemia (P = 0.03). ABCG2 was not associated with eGFR reductions when the SUA was <6.0 mg/dL. Among participants with SUA ≥6.0 mg/dL and eGFR 60-89 mL/min/1.73 m2, ≤50% ABCG2 function was associated with approximately 1.2-fold faster eGFR decline compared with fully functional ABCG2 (P = 0.02). Among the participants with SUA ≥6.0 mg/dL and eGFR 60-89 mL/min/1.73 m2, the adjusted eGFR slopes (given as mean ± standard error of the mean, in mL/min/1.73 m2 per year) were -0.946 ± 0.049, -1.040 ± 0.046, and -1.148 ± 0.069 for full, 75%, and ≤50% ABCG2 function, respectively. LIMITATIONS: Lack of measurement of urinary urate and uremic toxins that are known to be transported by ABCG2, and no independent validation cohort. CONCLUSIONS: Asymptomatic hyperuricemia was not associated with eGFR decline, except when in the presence of ≤50% ABCG2 function. PLAIN-LANGUAGE SUMMARY: The urate transporter ABCG2 is a protein that regulates serum urate concentrations; when dysfunctional, it can lead to elevated serum concentrations of this compound (ie, hyperuricemia). Although persistent hyperuricemia induces gout and kidney injury, the effects on organs during the asymptomatic phase have yet to be established. Therefore, to clarify the relationship between ABCG2, asymptomatic hyperuricemia, and kidney function, we conducted a retrospective cohort study of 1,885 healthy participants, including 311 participants with asymptomatic hyperuricemia. We found that the coexistence of asymptomatic hyperuricemia and severe ABCG2 dysfunction was associated with the age-dependent decline in kidney function. We concluded that asymptomatic hyperuricemia represents a risk factor for chronic kidney disease, at least in individuals with highly dysfunctional ABCG2. This new finding highlights the potential importance of ABCG2 in the pathogenesis of hyperuricemia-induced kidney injury.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Ohashi Y, Kuriyama S, Nakano T, et al. Urate Transporter ABCG2 Function and Asymptomatic Hyperuricemia: A Retrospective Cohort Study of CKD Progression. Am J Kidney Dis. 2022. PMID: 35810827. doi:10.1053/j.ajkd.2022.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。